ArticleCost effectiveness and resource allocation : C/E2021

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis.

Xueshan Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.